Long leukocyte telomere length at diagnosis is a risk factor for dementia progression in idiopathic parkinsonism

PLoS ONE

Volumn 9, Issue 12, 2014, Pages

  Degerman, Sofie ^a   Domellöf, Magdalena ^a   Lfors, Mattias ^a   Linder, Jan ^a   Lundin, Mathias ^a   Haraldsson, Susann ^a   Elgh, Eva ^a   Roos, Göran ^a   Forsgren, Lars ^a  

^a UMEÅ UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CLINICAL ASSESSMENT; CONTROLLED STUDY; DEMENTIA; DISEASE COURSE; DISEASE DURATION; FEMALE; FOLLOW UP; HUMAN; IDIOPATHIC PARKINSONISM; LEUKOCYTE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PARKINSON DISEASE; PARKINSONISM; PHENOTYPE; POLYMERASE CHAIN REACTION; PROGNOSIS; PROGRESSIVE SUPRANUCLEAR PALSY; SHY DRAGER SYNDROME; TELOMERE HOMEOSTASIS; VERY ELDERLY; GENETICS; METABOLISM; PATHOLOGY; PSYCHOLOGY; TELOMERE;

ADULT; AGED; AGED, 80 AND OVER; DEMENTIA; FEMALE; HUMANS; LEUKOCYTES; MALE; MIDDLE AGED; MULTIPLE SYSTEM ATROPHY; PARKINSON DISEASE; PROGNOSIS; SUPRANUCLEAR PALSY, PROGRESSIVE; TELOMERE;

EID: 84917691517     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0113387     Document Type: Article

References (27)

1. Hug N, Lingner J (2006) Telomere length homeostasis. Chromosoma 115: 413-425.
2. Kaszubowska L (2008) Telomere shortening and ageing of the immune system. J Physiol Pharmacol 59 Suppl 9: 169-186.
3. Schapira AH, Jenner P (2011) Etiology and pathogenesis of Parkinson's disease. Mov Disord 26: 1049-1055.
4. Cai Z, Yan LJ, Ratka A (2013) Telomere shortening and Alzheimer's disease. Neuromolecular Med 15: 25-48.
5. Maeda T, Guan JZ, Oyama J, Higuchi Y, Makino N (2009) Aging-associated alteration of subtelomeric methylation in Parkinson's disease. J Gerontol A Biol Sci Med Sci 64: 949-955.
6. Maeda T, Guan JZ, Koyanagi M, Higuchi Y, Makino N (2012) Aging-associated alteration of telomere length and subtelomeric status in female patients with Parkinson's disease. J Neurogenet 26: 245-251.
7. Watfa G, Dragonas C, Brosche T, Dittrich R, Sieber CC, et al. (2011) Study of telomere length and different markers of oxidative stress in patients with Parkinson's disease. J Nutr Health Aging 15: 277-281.
8. Eerola J, Kananen L, Manninen K, Hellstrom O, Tienari PJ, et al. (2010) No evidence for shorter leukocyte telomere length in Parkinson's disease patients. J Gerontol A Biol Sci Med Sci 65: 1181-1184.
9. Wang H, Chen H, Gao X, McGrath M, Deer D, et al. (2008) Telomere length and risk of Parkinson's disease. Mov Disord 23: 302-305.
10. Schurks M, Buring J, Dushkes R, Gaziano JM, Zee RY, et al. (2014) Telomere length and Parkinson's disease in men: a nested case-control study. Eur J Neurol 21: 93-99.
11. Hudson G, Faini D, Stutt A, Eccles M, Robinson L, et al. (2011) No evidence of substantia nigra telomere shortening in Parkinson's disease. Neurobiol Aging 32: 2107 e2103-2105.
12. Sanders JL, Newman AB (2013) Telomere Length in Epidemiology: A Biomarker of Aging, Age-Related Disease, Both, or Neither? Epidemiol Rev 35: 112-131.
13. Gibb WR, Lees AJ (1988) The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 51: 745-752.
14. Litvan I, Agid Y, Calne D, Campbell G, Dubois B, et al. (1996) Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology 47: 1-9.
15. Gilman S, Low PA, Quinn N, Albanese A, Ben-Shlomo Y, et al. (1999) Consensus statement on the diagnosis of multiple system atrophy. J Neurol Sci 163: 94-98.
16. Goetz CG, Poewe W, Rascol O, Sampaio C, Stebbins GT, et al. (2004) Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations. Mov Disord 19: 1020-1028.
17. Litvan I, Goldman JG, Troster AI, Schmand BA, Weintraub D, et al. (2012) Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. Mov Disord 27: 349-356.
18. Emre M (2007) Clinical features, pathophysiology and treatment of dementia associated with Parkinson's disease. Handb Clin Neurol 83: 401-419.
19. Domellöf ME (2013) Cognitive and motor dysfunction in the early phase of Parkinson's disease. Umeå University medical dissertations, ISSN 0346-6612; 1615.
20. Cawthon RM (2002) Telomere measurement by quantitative PCR. Nucleic Acids Res 30: e47.
21. Guan JZ, Maeda T, Sugano M, Oyama J, Higuchi Y, et al. (2008) A percentage analysis of the telomere length in Parkinson's disease patients. J Gerontol A Biol Sci Med Sci 63: 467-473.
22. Nordfjall K, Svenson U, Norrback KF, Adolfsson R, Lenner P, et al. (2009) The individual blood cell telomere attrition rate is telomere length dependent. PLoS Genet 5: e1000375.
23. Svenson U, Gronlund E, Soderstrom I, Sitaram RT, Ljungberg B, et al. (2013) Telomere length in relation to immunological parameters in patients with renal cell carcinoma. PLoS One 8: e55543.
24. Reynolds AD, Banerjee R, Liu J, Gendelman HE, Mosley RL (2007) Neuroprotective activities of CD4+CD25+ regulatory Tcells in an animal model of Parkinson's disease. J Leukoc Biol 82: 1083-1094.
25. Rosenkranz D, Weyer S, Tolosa E, Gaenslen A, Berg D, et al. (2007) Higher frequency of regulatory T cells in the elderly and increased suppressive activity in neurodegeneration. J Neuroimmunol 188: 117-127.
26. Saunders JA, Estes KA, Kosloski LM, Allen HE, Dempsey KM, et al. (2012) CD4+ regulatory and effector/memory T cell subsets profile motor dysfunction in Parkinson's disease. J Neuroimmune Pharmacol 7: 927-938.
27. Lee HJ, Bae EJ, Lee SJ (2014) Extracellular alpha-synuclein-a novel and crucial factor in Lewy body diseases. Nat Rev Neurol 10: 92-98.